Recent advances in preoperative chemotherapy have opened the possibility that some patients with HER2-positive breast cancer might avoid surgery altogether. HER2-positive breast cancer, which is characterized by the overproduction of the HER2 protein, often responds well to a combination of chemotherapy and targeted anti-HER2 drugs such as Herceptin. This approach can lead to significant tumour shrinkage, with approximately half of patients experiencing complete disappearance of their cancer.

The question now emerging among oncologists is whether surgery remains necessary for patients whose tumours have fully responded to preoperative treatment. Surgery for breast cancer can range from excising the tumour bed to full mastectomy, procedures that can carry substantial physical and psychological impacts. At institutions like The Royal Marsden and a few other cancer centres, the option to forego surgery in these cases is being explored cautiously. Early results have been promising, with no relapses reported in these patient groups so far.

One notable case illustrates this potential shift in treatment. An elderly patient in her early 90s, referred to as Jean, was diagnosed with a sizable HER2-positive breast cancer. Given her personal circumstances and reluctance to undergo extensive treatment, she was treated with a limited chemotherapy regimen complemented by Herceptin. After only three doses, her tumour shrank dramatically. She chose to discontinue chemotherapy but continued Herceptin and declined both surgery and radiotherapy. Despite the risks she accepted, eight years later she remains cancer-free and leading an active life. This case is especially significant because HER2-positive cancers typically recur within five years if they return at all.

Patients like Jean suggest the possibility that some breast cancers might be effectively cured with drug therapy alone, without the need for surgery. However, this approach remains experimental and has not yet been tested extensively in clinical trials, particularly regarding the omission of radiotherapy, which is still administered as a precaution in most cases.

Experts emphasize that breast cancer is not a uniform disease but rather a group of subtypes, each requiring tailored treatment strategies. The advancement in understanding these molecular differences has allowed more personalized approaches, potentially changing the standard care model for certain groups of patients. While the long-term outcomes of non-surgical management for HER2-positive breast cancer require further study, these developments underscore ongoing efforts to reduce the burden of treatment while maintaining effective cancer control.